Recipharm, a Swedish contract development and manufacturing organisation (CDMO), has entered into a long-term supply agreement with Tillotts Pharma of Switzerland.
The agreement includes technology transfer and commercial manufacturing of gastro-enterology products Entocort and Asacol.
The partnership will also involve the commercial scale development of Tillotts’ ongoing development programme for TP05, a potential treatment for acute ulcerative colitis.
All products are part of Tillotts’ focus on developing pharmaceutical products in the field of gastro-enterology.
Recipharm will provide advanced pellet coating technology for controlled release from its facility in Pessac, France.
The CDMO will also offer tablet and capsule manufacturing, including final packaging, from its facility in Fontaine, France.
Bottle filling will take place at Recipharm's site in Lisbon, Portugal.
The total investment across the Recipharm network to support this new business is €3.5 million. This includes investments to create new capacity as well as product specific investments.
Recipharm said the collaboration with Tillotts Pharma is an important step in the firm’s full service offering strategy, which allows customers to fulfil their needs for different technologies while working with Recipharm as a single partner.
This approach allows the CDMO to simplify the technology transfer and scale-up of projects, as well as ongoing commercial supply.
Kjell Johansson, President Manufacturing Services Europe at Recipharm, said: 'Our technical solutions offer a high level of customisation and we look forward to working with Tillotts to ensure the company's continued development and success within the gastro-enterology area.'
Mattias Norrman, COO of Tillotts Pharma, said: 'We have undertaken a thorough evaluation process to ensure we partner with a CDMO that can meet the needs we have for project management during technology transfer and scale-up, as well as fulfilling our requirements as a reliable commercial supplier.'